Expression of immune checkpoints in T cells of esophageal cancer patients
Metrics: PDF 4587 views | HTML 3066 views | ?
Jinhua Xie1,*, Ji Wang2,*, Shouliang Cheng3, Liangfeng Zheng3, Feiyue Ji3, Lin Yang4, Yan Zhang1, Haoming Ji1
1Cancer Center, Hai’an Hospital Affiliated to Nantong University, Hai’an, China
2Department of Oncology, the Second Affiliated Hospital of Soochow University, Suzhou, China
3The Central Laboratory, Hai’an Hospital Affiliated to Nantong University, Hai’an, China
4Cyrus Tang Hematology Center, Soochow University, Suzhou, China
Haoming Ji, email: [email protected]
Keywords: esophageal cancer, immune checkpoints, PD-1, TIM-3, cancer immunotherapy
Received: June 29, 2016 Accepted: August 16, 2016 Published: August 25, 2016
Inhibition of immune checkpoint proteins (checkpoints) has become a promising anti-esophageal cancer strategy. We here tested expressions of immune checkpoints in human esophageal cancers. Our results showed the expressions of many immune checkpoints, including CD28, CD27, CD137L, programmed death 1 (PD-1), T cell immunoglobulin mucin-3 (TIM-3), T cell Ig and ITIM domain (TIGIT), CD160, cytotoxic T lymphocyte antigen 4 (CTLA-4), CD200, CD137 and CD158, were dysregulated in peripheral T cells of esophageal cancer patients. Further, the expressions of PD-1, TIM-3 and TIGIT were upregulated in tumor infiltrating lymphocytes (TILs), which might be associated with TILs exhaustion. Meanwhile, the expressions of PD-1 and TIM-3 on CD4+ T cells were closely associated with clinic pathological features of esophageal cancer patients. These results indicate that co-inhibitory receptors PD-1, TIM-3 and TIGIT may be potential therapeutic oncotargets for esophageal cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.